Using mHealth to Optimize Pharmacotherapy Regimens
NCT04248517 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23
Last updated 2024-05-01
Summary
This project will use a smartphone technology to improve medication prescribing for individuals with FEP. We will collect real-time symptom and functioning data via smartphones to provide prescribers and other clinical team members with clinically relevant and time-sensitive information that will inform and promote shared decision making (SDM) and personalized interventions. The result will be a time-sensitive, data-driven, collaborative process to optimize medication regimens in order to maximize benefits, minimize harms, and promote adherence.
Conditions
- Schizophrenia
- First-Episode Psychosis
Interventions
- OTHER
-
mHealth Intervention
Participants will download the app onto their smartphone and complete ecological momentary assessements
Sponsors & Collaborators
-
Northwell Health, Early Treatment Program at Lenox Hill
collaborator UNKNOWN -
The Institute for Family Health Center for Counseling at Walton
collaborator UNKNOWN -
New York State Psychiatric Institute, Washington Heights Community Service
collaborator UNKNOWN -
BestSelf Behavioral Health
collaborator UNKNOWN -
National Institute of Mental Health (NIMH)
collaborator NIH -
New York State Psychiatric Institute
lead OTHER
Principal Investigators
-
Scott Stroup, MD, MPH · New York State Psychiatric Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 16 Years
- Max Age
- 30 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-09
- Primary Completion
- 2022-12-31
- Completion
- 2023-01-20
Countries
- United States
Study Locations
More Related Trials
-
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
NCT01175135 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone
NCT00892541 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
NCT02360319 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
NCT01192867 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
NCT01519557 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
NCT04512066 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study
NCT03289026 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Antipsychotics in Individuals at Clinical High-risk for Psychosis (the SHARP-2 Study)
NCT04010864 ·Status: UNKNOWN
-
Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia
NCT05278156 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
NCT00580125 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
NCT02469155 ·Status: COMPLETED ·Phase: PHASE3
-
Optimization of Acute Treatment in First Episode Schizophrenia
NCT00157378 ·Status: UNKNOWN ·Phase: PHASE4
-
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study
NCT00567710 ·Status: COMPLETED ·Phase: PHASE2
-
A Comparison of Long-acting Injectable Medications for Schizophrenia
NCT01136772 ·Status: COMPLETED ·Phase: PHASE4
-
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia
NCT02418819 ·Status: COMPLETED ·Phase: PHASE1
-
PREvent First Episode Relapse (PREFER)
NCT00220714 ·Status: UNKNOWN ·Phase: PHASE4
-
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
NCT02219009 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
NCT01149655 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
NCT01527305 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers
NCT01511510 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia
NCT07075237 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder
NCT00257075 ·Status: COMPLETED ·Phase: PHASE3
-
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
NCT00330863 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
NCT01009047 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients
NCT02109562 ·Status: COMPLETED ·Phase: PHASE3